ClinicalTrials.gg
TerminatedNCT01757691Updated May 4, 2015Results posted

Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)

A Phase 2 interventional study of Fingolimod 0.5mg/daily and Placebo in Acute Demylelinating Optic Neuritis, sponsored by Novartis Pharmaceuticals. Terminated at 2 sites in 2 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2015-05-04.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
Discontinuation of this study was based on Novartis decision to discontinue development of fingolimod for the treatment of ADON

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Optic Neuritis with a site in United States — 5 open to participants now, 7 under way, 2 of them phase 3. Optic Neuritis · United States.

Enrollment
18th of 20
2 · median 43
Started
2013
with 4 others
Phase 2
4 of 29
2 open now
Registered
13th of 29
by date

Among the 29 studies in Optic Neuritis with a site in United States, this one is the 18th largest by enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2013, is one of 4 in phase 2, and was the 13th registered.

Optic Neuritis

88 studies on the registry are indexed under Optic Neuritis; 16 are open to participants now.

Browse Optic Neuritis studies →

Open to participants now

5 of the 29 studies in Optic Neuritis with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Optic Neuritis studies recruiting now, 7 (50%) set no upper age limit and 6 (43%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Optic Neuritis with a site in United States, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of fingolimod 0.5mg versus placebo in patients with suspected acute demyelinating optic neuritis (ADON) receiving standard steroid treatment

03

Conditions studied

  • Acute Demylelinating Optic Neuritis

Browse trials for

Keywords

  • Acute demyelinating optic neuritis
  • Optic neuritis
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical signs and symptoms of ADON in one eye (loss of vision, pain on movement, impairment of color vision)
  • First episode of ADON
  • Able to undergo treatment with IV

Exclusion criteria

Exclusion Criteria:

  • History of any unexplained eye or neurological symptoms lasting longer than 48 hours
  • Optic neuritis in both eyes
  • Concomitant condition in either eye, other than optic neuritis
  • History of heart condition/disease
  • Patients with uncontrolled diabetes mellitus
  • Patients with liver conditions/disease
  • Inability to undergo MRI
  • Pregnant or nursing women
  • Women of who are not using highly effective method of

    • Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Fingolimod 0.5mg/daily

    Oral capsule dose was given once daily for 48 weeks

    Drug: Fingolimod 0.5mg/daily

  • Placebo comparator
    Placebo

    Patients received oral dose of placebo from Weeks 0-18, followed by oral dose of fingolimod 0.5/mg capsule from Weeks 18-48

    Drug: Placebo

Interventions

  • DrugFingolimod 0.5mg/daily

    Drug page: Fingolimod

    Also known as: FTY, Gilenya

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Mean Retinal Nerve Fiber Layer (RNFL) Thinning in Patients Treated With Fingolimod 0.5mg/Day, Relative to Patients Treated With Placebo

    Due to early termination and low patient enrollment the primary outcome measure was not analyzed

    Time frame: Baseline and Week 18

Secondary outcomes

  1. Low Contrast Visual Acuity (LCVA)

    Due to early termination and low patient enrollment this trial was not powered for efficacy

    Time frame: Baseline, Week 48

  2. Vision Based Quality of Life (QoL) Utility Score

    Due to early termination and low patient enrollment this trial was not powered for efficacy

    Time frame: Baseline, Week 18, Week 48

  3. Proportion of Paatients Converting to Either 2005 or 2010 McDonald MS or to CDMS

    Due to early termination and low patient enrollment this trial was not powered for efficacy

    Time frame: Baseline, Week 18, Week 48

  4. Number of Particpants With Adverse Events as a Measure of Safety and Tolerability

    Number of particpants with Adverse events as a measure of safety and tolerability

    Time frame: Weeks 0, 4, 8, 12, 18, 24, 36, 48, 60

07

Results

Posted May 4, 2015

Participant flow

Participant flow — Overall Study
MilestoneFingolimod 0.5mg/DailyPlacebo
Started20
Completed00
Not completed20
Withdrew: Administrative problems20

Outcome measures

PrimaryMean Retinal Nerve Fiber Layer (RNFL) Thinning in Patients Treated With Fingolimod 0.5mg/Day, Relative to Patients Treated With Placebo

Due to early termination and low patient enrollment the primary outcome measure was not analyzed

Time frame:
Baseline and Week 18

No measurements were reported for this outcome.

SecondaryLow Contrast Visual Acuity (LCVA)

Due to early termination and low patient enrollment this trial was not powered for efficacy

Time frame:
Baseline, Week 48

No measurements were reported for this outcome.

SecondaryVision Based Quality of Life (QoL) Utility Score

Due to early termination and low patient enrollment this trial was not powered for efficacy

Time frame:
Baseline, Week 18, Week 48

No measurements were reported for this outcome.

SecondaryProportion of Paatients Converting to Either 2005 or 2010 McDonald MS or to CDMS

Due to early termination and low patient enrollment this trial was not powered for efficacy

Time frame:
Baseline, Week 18, Week 48

No measurements were reported for this outcome.

SecondaryNumber of Particpants With Adverse Events as a Measure of Safety and Tolerability

Number of particpants with Adverse events as a measure of safety and tolerability

Time frame:
Weeks 0, 4, 8, 12, 18, 24, 36, 48, 60
Reported as:
Number · Participants
Number of Particpants With Adverse Events as a Measure of Safety and Tolerability
ParticipantsFingolimod 0.5mg/Daily
Adverse Events (AE)1
Death0
Non -Fatal Seriuos Aderse Event (SAE)0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fingolimod 0.5mg/Daily—0/2 (0%)1/2 (50%)
Placebo———
Most frequent other events
Most frequent other events
EventFingolimod 0.5mg/DailyPlacebo
VomitingGastrointestinal disorders1/2—
NasopharyngitisInfections and infestations1/2—
ASTHMA EXACERBATIONRespiratory, thoracic and mediastinal disorders1/2—

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Fingolimod 0.5mg/Daily
<=18 years0
Between 18 and 65 years2
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Fingolimod 0.5mg/Daily
Female2
Male0
08

Study locations

2 sites
  • Novartis Investigative Site
    St. Petersburg, Florida 33713, United States
  • Novartis Investigative Site
    Majadahonda, Madrid 28222, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in May 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2012
First posted
Dec 31, 2012
Start
Aug 2013
Primary completionActual
May 2014
CompletionActual
May 2014
Results first posted
May 4, 2015
Last update
May 4, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01757691
Responsible party
Sponsor
First posted
Dec 31, 2012
Start date
Aug 2013
Primary completion
May 2014
Completion
May 2014
Results posted
May 4, 2015
Last update
May 4, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion